<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; NVS</title>
	<atom:link href="http://www.stockbloghub.com/tag/nvs/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(JNJ) Healthcare Reform: Bad News for Big Pharma?</title>
		<link>http://www.stockbloghub.com/2012/04/04/jnj-healthcare-reform-bad-news-for-big-pharma/97425</link>
		<comments>http://www.stockbloghub.com/2012/04/04/jnj-healthcare-reform-bad-news-for-big-pharma/97425#comments</comments>
		<pubDate>Wed, 04 Apr 2012 16:56:03 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97425</guid>
		<description><![CDATA[Healthcare reform could be a minefield for Big Pharma in the long run. The Patient Protection and Affordable Care Act – less fondly known as “Obamacare” – was the big story to close out the month of March, as the Supreme Court officially took the case. In an effort to figure out which way the vote was going to swing, the media analyzed every word, pause and twitch the justices made. Though all of that heavy-duty analysis doesn’t actually prove anything; while the Court has likely already decided the healthcare mandate’s fate one way or the other, “We the People” probably won’t find out until June. Considering the political left’s repeated complaints about Solicitor General Donald Verrilli Jr. and Deputy Attorney General Edwin S. Kneedler’s admittedly painful performance in explaining ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/04/jnj-healthcare-reform-bad-news-for-big-pharma/97425/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Analyst Still Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2012/04/02/hgsi-human-genome-sciences-analyst-still-neutral-on-shares/97209</link>
		<comments>http://www.stockbloghub.com/2012/04/02/hgsi-human-genome-sciences-analyst-still-neutral-on-shares/97209#comments</comments>
		<pubDate>Mon, 02 Apr 2012 17:37:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sara Lee Corporation]]></category>
		<category><![CDATA[SLE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97209</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Human Genome Sciences Inc. (HGSI) with a target price of $8.25. Human Genome, founded in 1992 and based in Rockville, Maryland, is a biopharmaceutical company. The US launch of Benlysta in March 2011 for treating patients suffering from systemic lupus erythematosus (SLE) was a huge positive for Human Genome. The subsequent launch of the drug in Canada and several European nations, including Germany, Spain, Austria, Denmark, Finland, Hungary, Norway and Sweden is also encouraging. Benlysta, which has blockbuster potential, has been co-developed with GlaxoSmithKline (GSK). Benlysta is the first new lupus drug to be cleared in more than 50 years. Sales of the drug are growing, albeit slowly. Net sales of Benlysta improved 36.7% sequentially to $25.7 million in the final quarter of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/02/hgsi-human-genome-sciences-analyst-still-neutral-on-shares/97209/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Analyst Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2012/01/21/biib-biogen-analyst-neutral-on-shares/90609</link>
		<comments>http://www.stockbloghub.com/2012/01/21/biib-biogen-analyst-neutral-on-shares/90609#comments</comments>
		<pubDate>Sat, 21 Jan 2012 20:38:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PIMCO Municipal Income Fund II]]></category>
		<category><![CDATA[PML]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90609</guid>
		<description><![CDATA[We recently reiterated our Neutral recommendation on Biogen Idec (BIIB). Biogen is the market leader in therapies for the treatment of multiple sclerosis (MS). We believe the company will continue to retain a leading position in the MS market. Biogen’s largest product, Avonex, posted sales of $2,518.4 million, up 8.4%, in 2010. We expect Avonex to continue contributing significantly to the top-line thanks to price increases, focused marketing effort, expansion into new markets and positive clinical data. Meanwhile, Tysabri, the company’s second MS product, continues to see an increase in patients despite carrying a “black box” warning for the risk of progressive multifocal leukoencephalopathy (PML) and other cautionary language. Tysabri posted $1.2 billion in sales in 2010. Tysabri’s launch in new markets like India, Brazil, Argentina, the Middle East and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/21/biib-biogen-analyst-neutral-on-shares/90609/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis&#8217; Cancer Drug Afinitor Shows Promise for Breast Cancer</title>
		<link>http://www.stockbloghub.com/2011/12/12/nvs-novartis-cancer-drug-afinitor-shows-promise-for-breast-cancer/88414</link>
		<comments>http://www.stockbloghub.com/2011/12/12/nvs-novartis-cancer-drug-afinitor-shows-promise-for-breast-cancer/88414#comments</comments>
		<pubDate>Mon, 12 Dec 2011 22:12:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PFS]]></category>
		<category><![CDATA[Provident Financial Services Inc]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88414</guid>
		<description><![CDATA[Novartis’ (NVS) cancer drug Afinitor took a significant step forward, as the company once again presented encouraging data from late-stage trials of Afinitor for the treatment of breast cancer, an indication for which management estimates sales potential in excess of $1 billion. Afinitor is not yet approved for the treatment of breast cancer. The pivotal late-stage study (BOLERO-2) evaluated the use of Afinitor in combination with Pfizer’s (PFE) Aromasin (a hormonal therapy) in postmenopausal women with metastatic breast cancer whose disease has progressed, despite treatment with hormonal therapies like Novartis’ Femara or AstraZeneca’s (AZN) Arimidex. The long-term data showed that Afinitor plus Aromasin expanded progression-free survival (PFS), or time, without causing tumor growth in patients, by more than two times versus Aromasin alone. Treatment with Afinitor improved the PFS to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/12/nvs-novartis-cancer-drug-afinitor-shows-promise-for-breast-cancer/88414/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Emerging Markets: The Way Forward</title>
		<link>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206</link>
		<comments>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206#comments</comments>
		<pubDate>Wed, 07 Dec 2011 21:57:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88206</guid>
		<description><![CDATA[According to Irish orator, philosopher, &#38; politician Edmund Burke, change is the most powerful law of nature. The winds of change seem to be sweeping across the pharmaceutical industry as well. Until recently, most commercialization efforts were focused on the U.S. &#8212; the largest pharmaceutical market &#8212; along with Europe and Japan. However, with factors like pricing pressure in the European Union (EU) and intensifying generic competition affecting sales in large pharmaceutical markets, many leading players in the pharmaceutical space such as Pfizer (PFE), Bristol &#8211; Myers Squibb Company (BMY), Merck (MRK), Eli Lilly (LLY), GlaxoSmithKline (GSK), Astra Zeneca (AZN) and Sanofi-Aventis (SNY), have shifted their focus on emerging (&#8220;pharmerging&#8221;) markets. The key emerging markets targeted by big players in the pharmaceutical space (aka “Big Pharma&#8221;) include China, Russia, Brazil, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Earns FDA Approval</title>
		<link>http://www.stockbloghub.com/2011/12/05/myl-mylan-earns-fda-approval/88071</link>
		<comments>http://www.stockbloghub.com/2011/12/05/myl-mylan-earns-fda-approval/88071#comments</comments>
		<pubDate>Tue, 06 Dec 2011 00:54:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WCRX]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88071</guid>
		<description><![CDATA[Generic maker, Mylan Inc. (MYL) recently announced that its Indian subsidiary Mylan Laboratories has received tentative approval from the US Food &#38; Drug Administration (FDA) for a fixed-dose combination of generic versions of Bristol Myers Squibb’s (BMY) drug Reyataz and Abbott Labs&#8216; (ABT) Norvir for the treatment of HIV/AIDS. The fixed drug combination has been pre-qualified to be used in treatment of experienced patients by the World Health Organization (WHO). It can also be used in combination with other antiretroviral (ARV) agents and will be eligible for purchase in certain developing countries. The drug was approved through the President&#8217;s Emergency Plan for AIDS Relief (PEPFAR). The drug will boost Mylan’s already strong portfolio of ARV’s in India. In a separate development, Mylan announced that Warner Chilcott Company (WCRX) filed a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/05/myl-mylan-earns-fda-approval/88071/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Completes Trial Enrollment</title>
		<link>http://www.stockbloghub.com/2011/12/02/alny-alnylam-pharmaceuticals-completes-trial-enrollment/87898</link>
		<comments>http://www.stockbloghub.com/2011/12/02/alny-alnylam-pharmaceuticals-completes-trial-enrollment/87898#comments</comments>
		<pubDate>Fri, 02 Dec 2011 16:19:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87898</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc. (ALNY) recently announced it has completed enrollment in a mid-stage study of its pipeline candidate ALN-RSV01, an RNA interference technology (RNAi) therapeutic being studied for the treatment of respiratory syncytial virus (RSV) infection. The study is being conducted in RSV-infected lung transplant patients at 33 lung transplant centers in six countries. Data from the study is expected in mid-2012. Alnylam is developing ALN-RSV01 on its own while Cubist Pharmaceuticals (CBST) has the opt-in right to collaborate with the company in future for the lung transplant indication. Kyowa Hakko Kirin has opt-in rights for the candidate in Asia. Alnylam’s RNAi technology is potentially revolutionary. Alnylam is utilizing this know-how for selectively turning off the activity of certain genes to build a pipeline of drug candidates to treat a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/02/alny-alnylam-pharmaceuticals-completes-trial-enrollment/87898/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Approved for Zinecard Generic</title>
		<link>http://www.stockbloghub.com/2011/12/01/myl-mylan-approved-for-zinecard-generic/87803</link>
		<comments>http://www.stockbloghub.com/2011/12/01/myl-mylan-approved-for-zinecard-generic/87803#comments</comments>
		<pubDate>Thu, 01 Dec 2011 14:57:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87803</guid>
		<description><![CDATA[Mylan, Inc.’s (MYL) generic business was boosted further with the approval from the U.S. Food and Drug Administration (FDA) for its generic version of Pharmacia &#38; Upjohn&#8217;s Zinecard injection. Zinecard injection, which is a chemoprotective agent, recorded revenue of approximately $3.4 million for the trailing twelve months ending in September 2011. As of November 28, 2011, the company had 161 abbreviated new drug applications (ANDAs) that were pending clearance by the FDA, targeting $97.7 billion in branded sales. Mylan believes that about 43 of these ANDAs are first-to-file opportunities, representing more than $26.9 billion in branded sales. Earlier this month Mylan reached a settlement agreement with Novartis (NVS) relating to the generic version of the latter’s bioidentical estrogen therapy Vivelle-Dot. As a result of the resolution, the lawsuit filed by ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/01/myl-mylan-approved-for-zinecard-generic/87803/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis&#8217; Rasitrio Cleared in European Union</title>
		<link>http://www.stockbloghub.com/2011/11/28/nvs-novartis-rasitrio-cleared-in-european-union/87648</link>
		<comments>http://www.stockbloghub.com/2011/11/28/nvs-novartis-rasitrio-cleared-in-european-union/87648#comments</comments>
		<pubDate>Mon, 28 Nov 2011 20:34:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87648</guid>
		<description><![CDATA[Novartis (NVS) recently announced that its triple combination hypertension pill Rasitrio has been cleared in the European Union (EU). Rasitrio combines the currently marketed hypertension pill Razilez (marketed as Tekturna in the US) with amlodipine and hydrochlorothiazide (HCT). The pill is already marketed as Amturnide in the US. The approval of Rasitrio was based on data from late stage trials which showed that the drug significantly reduced blood pressure as compared to dual combinations of each of its individual components. The positive effect of Rasitrio was seen within a week of starting treatment and was maintained for the entire 24-hour dose interval. The approval of Rasitrio is a definite boon for sufferers of hypertension as most (almost 85%) have to recourse to multiple medicines to control their blood pressure. Novartis ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/28/nvs-novartis-rasitrio-cleared-in-european-union/87648/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Settles with Novartis</title>
		<link>http://www.stockbloghub.com/2011/11/28/myl-mylan-settles-with-novartis/87474</link>
		<comments>http://www.stockbloghub.com/2011/11/28/myl-mylan-settles-with-novartis/87474#comments</comments>
		<pubDate>Mon, 28 Nov 2011 16:41:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87474</guid>
		<description><![CDATA[Mylan, Inc. (MYL) recently announced a settlement agreement with Novartis (NVS) relating to the generic version of Novartis’ bioidentical estrogen therapy Vivelle-Dot. As a result of the resolution, the lawsuit filed by Novartis will be dismissed and Mylan can launch a generic version of Vivelle-Dot on December 16, 2013, or earlier under certain circumstances. Mylan was the first to file an abbreviated new drug application (ANDA) with the US Food &#38; Drug Administration (FDA) to market the generic version of the drug. Accordingly, Mylan will enjoy an exclusivity period of 180 days when it will be the sole company to market the generic. The deal is subject to review by the US Department of Justice and the Federal Trade Commission. Earlier this month, Mylan entered into an agreement with Pfizer, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/28/myl-mylan-settles-with-novartis/87474/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Reveals ALNTTR01 Trial Data</title>
		<link>http://www.stockbloghub.com/2011/11/28/alny-alnylam-pharmaceuticals-reveals-alnttr01-trial-data/87547</link>
		<comments>http://www.stockbloghub.com/2011/11/28/alny-alnylam-pharmaceuticals-reveals-alnttr01-trial-data/87547#comments</comments>
		<pubDate>Mon, 28 Nov 2011 16:32:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87547</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc. (ALNY) recently presented data from an early stage study of its pipeline candidate ALN-TTR01 at a scientific conference in Japan. ALN-TTR01 is a systemically delivered RNA interference technology (RNAi) therapeutic that employs a first-generation lipid nanoparticles (LNP) formulation to treat transthyretin (TTR) mediated amyloidosis (ATTR). Data from the trials showed that ALN-TTR01 led to statistically significant reductions in serum TTR protein levels for the treatment of ATTR. Overall, the candidate has proved to be well tolerated with no serious adverse events observed in the study. We believe the encouraging data further highlights the potential of RNAi as a new class of therapeutics. This is the first time an RNAi has silenced a disease-causing gene in clinical trials. ALN-TTR01 is part of Alnylam’s core product strategy, Alnylam 5&#215;15, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/28/alny-alnylam-pharmaceuticals-reveals-alnttr01-trial-data/87547/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MNTA) Momenta Pharmaceuticals and Novartis AG Sue Watson Pharmaceuticals</title>
		<link>http://www.stockbloghub.com/2011/09/24/mnta-momenta-pharmaceuticals-and-novartis-ag-sue-watson-pharmaceuticals/83960</link>
		<comments>http://www.stockbloghub.com/2011/09/24/mnta-momenta-pharmaceuticals-and-novartis-ag-sue-watson-pharmaceuticals/83960#comments</comments>
		<pubDate>Sat, 24 Sep 2011 18:58:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[MNTA]]></category>
		<category><![CDATA[Momenta Pharmaceuticals Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83960</guid>
		<description><![CDATA[Momenta Pharmaceuticals, Inc. (MNTA) and Novartis AG (NVS) filed a lawsuit against Amphastar Pharmaceuticals, Inc. and Watson Pharmaceuticals Inc. (WPI) regarding the generic version of Sanofi-Aventis’ (SNY) Lovenox. The lawsuit was filed in United States District Court for the District of Massachusetts. The lawsuit claims that Amphastar Pharma&#8217;s generic Lovenox, which was approved by the US Food and Administration (FDA) on September 19, infringes two of Momenta&#8217;s US patents. Amphastar Pharma plans to launch generic Lovenox in the US in the fourth quarter of 2011. Lovenox is indicated for the prophylaxis and treatment of deep vein thrombosis and prophylaxis of ischemic complications in unstable angina and non-Q-wave myocardial infarction. According to IMS Health, US sales of Lovenox and its generic equivalents amounted to about $2.6 billion for the twelve months ended ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/24/mnta-momenta-pharmaceuticals-and-novartis-ag-sue-watson-pharmaceuticals/83960/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Settles with Roche for Xeloda</title>
		<link>http://www.stockbloghub.com/2011/09/23/myl-mylan-settles-with-roche-for-xeloda/83911</link>
		<comments>http://www.stockbloghub.com/2011/09/23/myl-mylan-settles-with-roche-for-xeloda/83911#comments</comments>
		<pubDate>Fri, 23 Sep 2011 19:05:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83911</guid>
		<description><![CDATA[Mylan Inc. (MYL) recently announced that it has entered into a settlement and license agreement with Roche (RHHBY) bringing an end to its ongoing litigation with the latter relating to Roche’s cancer drug Xeloda. Mylan was looking to launch a generic version of the drug which is used for the treatment of metastatic breast and colorectal cancers. Xeloda generated revenue of $570 million in the trailing twelve months ending June 30, 2011, according to IMS Health. The details of the agreement have been kept confidential. The agreement will be applicable once it is reviewed by the US Department of Justice and the Federal Trade Commission. Mylan also recently announced that its Indian subsidiary, Matrix, has received tentative approval from the US Food and Drug Administration (FDA) to market a novel ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/23/myl-mylan-settles-with-roche-for-xeloda/83911/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Drug Cleared in European Union for SEGA</title>
		<link>http://www.stockbloghub.com/2011/09/20/nvs-novartis-drug-cleared-in-eu-for-sega/83127</link>
		<comments>http://www.stockbloghub.com/2011/09/20/nvs-novartis-drug-cleared-in-eu-for-sega/83127#comments</comments>
		<pubDate>Tue, 20 Sep 2011 19:12:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83127</guid>
		<description><![CDATA[Novartis (NVS) recently received a boost when its drug Votubia was approved for the treatment of subependymal giant cell astrocytomas (SEGA), a benign brain tumor associated with tuberous sclerosis (TS) in the European Union (EU). For the first time ever will such a medication be available in this region for the treatment of this challenging disease. Votubia is already marketed in the US under the trade name Afinitor for the disease. It is also approved in Switzerland, Brazil, Colombia, Guatemala, the Philippines and South Korea to treat SEGA associated with TS. Earlier in June this year, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Votubia for the indication. The recommendation was based on data from a mid-stage study, which showed ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/nvs-novartis-drug-cleared-in-eu-for-sega/83127/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Neuroendocrine Tumors Drug Cleared in European Union</title>
		<link>http://www.stockbloghub.com/2011/09/11/nvs-novartis-neuroendocrine-tumors-drug-cleared-in-european-union/82655</link>
		<comments>http://www.stockbloghub.com/2011/09/11/nvs-novartis-neuroendocrine-tumors-drug-cleared-in-european-union/82655#comments</comments>
		<pubDate>Sun, 11 Sep 2011 19:54:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Arlington Asset Investment Corporation]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Stephan Company]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[TSC]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82655</guid>
		<description><![CDATA[Novartis’(NVS) drug Afinitor was recently approved in the European Union (EU) for the treatment of patients with advanced neuroendocrine tumors (NET) of pancreatic origin with progressive disease. The drug is already approved in the US for the indication. The approval was based on the RADIANT-3 trial which demonstrated that Afinitor led to a statistically significant improvement in progression-free survival versus placebo. The number of months of survival without the disease progressing was 11 months for a patient treated with Afinitor versus 4.6 months for a patient on placebo. Afinitor is currently marketed for the treatment of advanced renal cell carcinoma (kidney cancer) after an anti-VEGF therapy like Roche’s (RHHBY) Avastin, Pfizer’s (PFE) Sutent or Onyx Pharmaceuticals’(ONXX) Nexavar in the US and EU. In June this year, the Committee for Medicinal ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/11/nvs-novartis-neuroendocrine-tumors-drug-cleared-in-european-union/82655/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Earns Favorable Court Ruling</title>
		<link>http://www.stockbloghub.com/2011/09/01/teva-teva-pharmaceutical-industries-earns-favorable-court-ruling/82359</link>
		<comments>http://www.stockbloghub.com/2011/09/01/teva-teva-pharmaceutical-industries-earns-favorable-court-ruling/82359#comments</comments>
		<pubDate>Thu, 01 Sep 2011 16:57:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Canadian Pacific Railway Limited]]></category>
		<category><![CDATA[CP]]></category>
		<category><![CDATA[MNTA]]></category>
		<category><![CDATA[Momenta Pharmaceuticals Inc]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82359</guid>
		<description><![CDATA[Teva Pharmaceutical Industries Ltd. (TEVA) recently received a boost with the US District Court for the Southern District of New York issuing a favorable ruling related to the company’s patent infringement lawsuit against Novartis AG (NVS)/Momenta Pharmaceuticals, Inc. (MNTA) and Mylan Inc. (MYL)/Natco Pharma Ltd. The lawsuit is regarding the company’s lead drug Copaxone, marketed for the treatment of multiple sclerosis (MS). The Court adopted all relevant claim construction interpretations of Teva and rejected all the claim construction interpretations put forth by Novartis/Momenta and Mylan/Natco. Moreover, the Court denied Mylan&#8217;s motion for summary judgment that the disputed patents are invalid for indefiniteness. We note that Teva’s patent for Copaxone is set to expire in 2014. The company has filed a Citizen Petition (CP) with the US Food and Drug Administration ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/01/teva-teva-pharmaceutical-industries-earns-favorable-court-ruling/82359/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322</link>
		<comments>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322#comments</comments>
		<pubDate>Tue, 30 Aug 2011 21:15:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82322</guid>
		<description><![CDATA[We have maintained a Neutral rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $7.00 per share. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough technology known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this know-how to build a pipeline of drug candidates for the treatment of a wide array of diseases. Alnylam Pharmaceuticals Inc.’s second quarter 2011 loss of 33 cents per share was narrower than the Zacks Consensus Estimate of a loss of 37 cents per share and the year-ago loss of 35 cents per share. Lower operating expenses led to the narrower loss despite lukewarm revenues in the quarter. Revenues for the reported quarter fell 22.6% from the prior year to $20.6 million. Revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Analyst Reaffirms Shares at Neutral</title>
		<link>http://www.stockbloghub.com/2011/08/25/myl-mylan-analyst-reaffirms-shares-at-neutral/81823</link>
		<comments>http://www.stockbloghub.com/2011/08/25/myl-mylan-analyst-reaffirms-shares-at-neutral/81823#comments</comments>
		<pubDate>Thu, 25 Aug 2011 16:48:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81823</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Mylan Inc. (MYL) with a target price of $19.00 following an appraisal of second quarter 2011 financial results. Mylan’s second quarter 2011 earnings (excluding special items) of 52 cents per share were above the Zacks Consensus Estimate of 45 cents and also beat the year-ago earnings 37 cents. Earnings growth was driven by an increase in generics revenue and improved gross margins. Mylan reports revenues from two segments: Generics and Specialty. Generic revenues grew 17% to $1.44 billion in the second quarter of 2011 as a decline in the Europe, Middle East &#38; Africa (EMEA) market was offset by growth in other markets like Asia-Pacific and North America. Mylan is one of the leading players in the generics market. A large number of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/25/myl-mylan-analyst-reaffirms-shares-at-neutral/81823/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Analyst Maintains Neutral Recommendation</title>
		<link>http://www.stockbloghub.com/2011/08/22/hgsi-human-genome-sciences-analyst-maintains-neutral-recommendation/81747</link>
		<comments>http://www.stockbloghub.com/2011/08/22/hgsi-human-genome-sciences-analyst-maintains-neutral-recommendation/81747#comments</comments>
		<pubDate>Mon, 22 Aug 2011 14:47:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sara Lee Corporation]]></category>
		<category><![CDATA[SLE]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81747</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Human Genome Sciences Inc. (HGSI) with a target price of $16.00. Human Genome, founded in 1992 and based in Rockville, Maryland, is a biopharmaceutical company. The US launch of Benlysta earlier in the year for treating patients suffering from systemic lupus erythematosus (SLE) is a huge positive for Human Genome. The subsequent approvals of the drug in the European Union (EU) and Canada are also encouraging. The drug, which has blockbuster potential, has been co-developed with GlaxoSmithKline (GSK). Benlysta is the first new lupus drug to be cleared in more than 50 years. Lupus is a potentially fatal autoimmune disease that is extremely difficult to treat. We believe that the approval of this potentially blockbuster candidate will drive Human Genome to profitability. Benlysta ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/22/hgsi-human-genome-sciences-analyst-maintains-neutral-recommendation/81747/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan and Endo Pharmaceuticals in Legal Tussle</title>
		<link>http://www.stockbloghub.com/2011/08/18/myl-mylan-and-endo-pharmaceuticals-in-legal-tussle/81630</link>
		<comments>http://www.stockbloghub.com/2011/08/18/myl-mylan-and-endo-pharmaceuticals-in-legal-tussle/81630#comments</comments>
		<pubDate>Thu, 18 Aug 2011 22:40:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81630</guid>
		<description><![CDATA[Mylan Inc. (MYL) recently announced that Endo Pharmaceuticals (ENDP) filed a patent infringement lawsuit in connection with an abbreviated new drug application (ANDA) filed by Mylan with the US Food and Drug Administration (FDA) for the generic version of Endo’s acute migraine drug Frova. Mylan believes it is the first company to file an ANDA for generic Frova and is expecting to be granted 180 days of marketing exclusivity once approved. Frova generated revenues of approximately $68.2 million in the trailing twelve months ending on June 30, 2011. This month, Mylan launched the generic version of Uroxatral tablets. Some important products launched by Mylan in the recent past include generic versions of AstraZeneca&#8216;s (AZN) Entocort, Novartis&#8216; (NVS) Femara and Cephalon&#8216;s (CEPH) Amrix. Mylan has a robust generic pipeline. As of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/18/myl-mylan-and-endo-pharmaceuticals-in-legal-tussle/81630/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Beats Second Quarter Earnings on All Fronts</title>
		<link>http://www.stockbloghub.com/2011/07/27/myl-mylan-beats-second-quarter-earnings-on-all-fronts/80033</link>
		<comments>http://www.stockbloghub.com/2011/07/27/myl-mylan-beats-second-quarter-earnings-on-all-fronts/80033#comments</comments>
		<pubDate>Thu, 28 Jul 2011 04:22:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80033</guid>
		<description><![CDATA[Mylan Inc.’s (MYL) second quarter 2011 earnings (excluding special items) of 52 cents per share were above the Zacks Consensus Estimate of 45 cents as well as the year-ago earnings of 37 cents per share. Earnings growth was driven by increase in generics revenue and improved gross margins. Quarter in Details Total revenues at Mylan climbed 15% over the prior year to $1.57 billion driven by increased sales of generic drugs and the positive impact of foreign exchange (Fx). Revenues were also ahead of the Zacks Consensus Estimate of $1.50 billion. Total revenues comprise both net revenues and other revenues from third parties. Mylan reports revenues through two segments: Generics and Specialty. Generic third party net sales, derived from sales in North America, Europe, Middle East &#38; Africa (EMEA), and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/27/myl-mylan-beats-second-quarter-earnings-on-all-fronts/80033/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AIXG) Company News for July 20, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/07/20/aixg-company-news-for-july-20-2011-corporate-summary/79447</link>
		<comments>http://www.stockbloghub.com/2011/07/20/aixg-company-news-for-july-20-2011-corporate-summary/79447#comments</comments>
		<pubDate>Wed, 20 Jul 2011 15:28:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diversified Machinery]]></category>
		<category><![CDATA[Industrial Goods]]></category>
		<category><![CDATA[AIXG]]></category>
		<category><![CDATA[Aixtron AG]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[BRCM]]></category>
		<category><![CDATA[Broadcom Corporation]]></category>
		<category><![CDATA[Check Point Software Technologies Limited]]></category>
		<category><![CDATA[CHKP]]></category>
		<category><![CDATA[Cisco Systems]]></category>
		<category><![CDATA[CMA]]></category>
		<category><![CDATA[Comerica Incorporated]]></category>
		<category><![CDATA[CSCO]]></category>
		<category><![CDATA[KO]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[OMC]]></category>
		<category><![CDATA[Omnicom Group Inc.]]></category>
		<category><![CDATA[State Street Corporation]]></category>
		<category><![CDATA[STT]]></category>
		<category><![CDATA[The Coca-Cola Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79447</guid>
		<description><![CDATA[•    Coca-Cola Company (NYSE:KO) reported Q2 EPS of $1.20, ahead of the Zacks Consensus Estimate of $1.16 per share. Revenues for the quarter rose 47% year-over-year to $12.7 billion, beating the Zacks Consensus Estimate of $12.364 billion •    Bank of America (NYSE:BAC) reported adjusted Q2 EPS of $0.33, surpassing the Zacks Consensus Estimate for a loss of $0.91 per share. Revenues for the quarter came in at $13.48 billion, lower than the Zacks Consensus Estimate of $25.286 billion •    Omnicom Group (NYSE:OMC) reported Q2 EPS of $0.96, beating the Zacks Consensus Estimate of $0.92 per share. Revenues for the quarter rose 15% year-over-year to $3.49 billion, ahead of the Zacks Consensus Estimate of $3.381 billion •    State Street Corp. (NYSE:STT) reported Q2 EPS of $0.96, marginally lower than the Zacks ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/20/aixg-company-news-for-july-20-2011-corporate-summary/79447/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AAPL) 2011 Second Quarter Earnings Preview &#8211; Detailed</title>
		<link>http://www.stockbloghub.com/2011/07/18/aapl-2011-second-quarter-earnings-preview-detailed/79251</link>
		<comments>http://www.stockbloghub.com/2011/07/18/aapl-2011-second-quarter-earnings-preview-detailed/79251#comments</comments>
		<pubDate>Mon, 18 Jul 2011 21:09:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Personal Computers]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[8x8 Inc]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[ABB]]></category>
		<category><![CDATA[ABB Limited]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Acacia Research Corporation]]></category>
		<category><![CDATA[Acme Packet Inc]]></category>
		<category><![CDATA[ACTG]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Advanced Micro Devices Inc.]]></category>
		<category><![CDATA[AF]]></category>
		<category><![CDATA[Air Products & Chemicals Inc.]]></category>
		<category><![CDATA[Alaska Air Group Inc.]]></category>
		<category><![CDATA[ALB]]></category>
		<category><![CDATA[Albemarle Corporation]]></category>
		<category><![CDATA[Alexion Pharmaceuticals Inc]]></category>
		<category><![CDATA[ALK]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[Altera Corporation]]></category>
		<category><![CDATA[ALTR]]></category>
		<category><![CDATA[Altria Group Inc.]]></category>
		<category><![CDATA[ALV]]></category>
		<category><![CDATA[ALXN]]></category>
		<category><![CDATA[AMD]]></category>
		<category><![CDATA[American Express Company]]></category>
		<category><![CDATA[AmeriServ Financial Inc]]></category>
		<category><![CDATA[Amphenol Corporation]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[AMR Corporation]]></category>
		<category><![CDATA[AMSG]]></category>
		<category><![CDATA[AmSurg Corporation]]></category>
		<category><![CDATA[AMTD]]></category>
		<category><![CDATA[AO Smith Corporation]]></category>
		<category><![CDATA[AOS]]></category>
		<category><![CDATA[APD]]></category>
		<category><![CDATA[APH]]></category>
		<category><![CDATA[APKT]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[AptarGroup Inc.]]></category>
		<category><![CDATA[ARB]]></category>
		<category><![CDATA[Arbitron Inc]]></category>
		<category><![CDATA[ASBC]]></category>
		<category><![CDATA[ASR]]></category>
		<category><![CDATA[ASRV]]></category>
		<category><![CDATA[Associated Banc-Corp]]></category>
		<category><![CDATA[Astoria Financial Corporation]]></category>
		<category><![CDATA[AT Cross Company]]></category>
		<category><![CDATA[AT&T Inc.]]></category>
		<category><![CDATA[Athenahealth Inc]]></category>
		<category><![CDATA[ATHN]]></category>
		<category><![CDATA[ATMI]]></category>
		<category><![CDATA[ATMI Inc.]]></category>
		<category><![CDATA[ATR]]></category>
		<category><![CDATA[ATX]]></category>
		<category><![CDATA[Autoliv Inc.]]></category>
		<category><![CDATA[AVID]]></category>
		<category><![CDATA[Avid Technology Inc]]></category>
		<category><![CDATA[AXP]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Badger Meter Inc]]></category>
		<category><![CDATA[BancFirst Corporation]]></category>
		<category><![CDATA[Banco Latinoamericano de Exportaciones SA]]></category>
		<category><![CDATA[Bancorp Rhode Island Inc]]></category>
		<category><![CDATA[BANF]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[Banner Corporation]]></category>
		<category><![CDATA[BANR]]></category>
		<category><![CDATA[BARI]]></category>
		<category><![CDATA[BAS]]></category>
		<category><![CDATA[Basic Energy Services Inc.]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BB & T Corporation]]></category>
		<category><![CDATA[BBT]]></category>
		<category><![CDATA[BJ's Restaurants Inc.]]></category>
		<category><![CDATA[BJRI]]></category>
		<category><![CDATA[BK]]></category>
		<category><![CDATA[BlackRock Inc.]]></category>
		<category><![CDATA[BLDR]]></category>
		<category><![CDATA[BLK]]></category>
		<category><![CDATA[BLX]]></category>
		<category><![CDATA[BMI]]></category>
		<category><![CDATA[BOOT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BPOP]]></category>
		<category><![CDATA[BRO]]></category>
		<category><![CDATA[Brown & Brown Inc.]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[BTU]]></category>
		<category><![CDATA[Builders FirstSource Inc]]></category>
		<category><![CDATA[BX]]></category>
		<category><![CDATA[CA]]></category>
		<category><![CDATA[Ca Technologies]]></category>
		<category><![CDATA[CAKE]]></category>
		<category><![CDATA[Cardinal Financial Corporation]]></category>
		<category><![CDATA[Cash America International Inc]]></category>
		<category><![CDATA[CAT]]></category>
		<category><![CDATA[Caterpillar Inc.]]></category>
		<category><![CDATA[Cathay General Bancorp]]></category>
		<category><![CDATA[CATY]]></category>
		<category><![CDATA[CB]]></category>
		<category><![CDATA[CBE]]></category>
		<category><![CDATA[CBI]]></category>
		<category><![CDATA[CCK]]></category>
		<category><![CDATA[CE]]></category>
		<category><![CDATA[Celanese Corporation]]></category>
		<category><![CDATA[Celestica Inc.]]></category>
		<category><![CDATA[Cemex S.A.B. de C.V.]]></category>
		<category><![CDATA[Central Valley Community Bancorp]]></category>
		<category><![CDATA[Cepheid]]></category>
		<category><![CDATA[CFNL]]></category>
		<category><![CDATA[Charles Schwab Corporation]]></category>
		<category><![CDATA[Check Point Software Technologies Limited]]></category>
		<category><![CDATA[Chicago Bridge & Iron Company N.V.]]></category>
		<category><![CDATA[Chipotle Mexican Grill Inc.]]></category>
		<category><![CDATA[CHKP]]></category>
		<category><![CDATA[Cintas Corporation]]></category>
		<category><![CDATA[Cirrus Logic Inc.]]></category>
		<category><![CDATA[City National Corporation]]></category>
		<category><![CDATA[CLB]]></category>
		<category><![CDATA[CLS]]></category>
		<category><![CDATA[CMA]]></category>
		<category><![CDATA[CMCO]]></category>
		<category><![CDATA[CMG]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[CoBiz Financial Inc]]></category>
		<category><![CDATA[COBZ]]></category>
		<category><![CDATA[Coca-Cola FEMSA S.A.B de CV]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[COHU]]></category>
		<category><![CDATA[Cohu Inc]]></category>
		<category><![CDATA[COL]]></category>
		<category><![CDATA[Columbus Mckinnon Corporation]]></category>
		<category><![CDATA[Comerica Incorporated]]></category>
		<category><![CDATA[Complete Production Services Inc]]></category>
		<category><![CDATA[Compuware Corporation]]></category>
		<category><![CDATA[Cooper Industries Limited]]></category>
		<category><![CDATA[Core Laboratories NV]]></category>
		<category><![CDATA[Covanta Holding Corporation]]></category>
		<category><![CDATA[CPHD]]></category>
		<category><![CDATA[CPWR]]></category>
		<category><![CDATA[CPX]]></category>
		<category><![CDATA[Crown Holdings Inc.]]></category>
		<category><![CDATA[CRUS]]></category>
		<category><![CDATA[CSH]]></category>
		<category><![CDATA[CSX]]></category>
		<category><![CDATA[CSX Corporation]]></category>
		<category><![CDATA[CTAS]]></category>
		<category><![CDATA[CVA]]></category>
		<category><![CDATA[CVB Financial Corporation]]></category>
		<category><![CDATA[CVBF]]></category>
		<category><![CDATA[CVCY]]></category>
		<category><![CDATA[CX]]></category>
		<category><![CDATA[CY]]></category>
		<category><![CDATA[Cymer Inc.]]></category>
		<category><![CDATA[CYMI]]></category>
		<category><![CDATA[CYN]]></category>
		<category><![CDATA[Cypress Semiconductor Corporation]]></category>
		<category><![CDATA[CYT]]></category>
		<category><![CDATA[Cytec Industries Inc.]]></category>
		<category><![CDATA[DAL]]></category>
		<category><![CDATA[Danaher Corporation]]></category>
		<category><![CDATA[Datalink Corporation]]></category>
		<category><![CDATA[Delta Air Lines Inc.]]></category>
		<category><![CDATA[DGII]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[DHR]]></category>
		<category><![CDATA[Diamond Offshore Drilling Inc]]></category>
		<category><![CDATA[Digi International Inc.]]></category>
		<category><![CDATA[DO]]></category>
		<category><![CDATA[DOV]]></category>
		<category><![CDATA[Dover Corporation]]></category>
		<category><![CDATA[DTLK]]></category>
		<category><![CDATA[E*TRADE Financial Corporation]]></category>
		<category><![CDATA[Eagle Bancorp Inc]]></category>
		<category><![CDATA[East West Bancorp Inc]]></category>
		<category><![CDATA[Eastern Virginia Bankshares Inc]]></category>
		<category><![CDATA[EastGroup Properties Inc]]></category>
		<category><![CDATA[EBAY]]></category>
		<category><![CDATA[eBay Inc.]]></category>
		<category><![CDATA[ECA]]></category>
		<category><![CDATA[EDR]]></category>
		<category><![CDATA[EDU]]></category>
		<category><![CDATA[Education Realty Trust Inc]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EFII]]></category>
		<category><![CDATA[EGBN]]></category>
		<category><![CDATA[EGHT]]></category>
		<category><![CDATA[EGP]]></category>
		<category><![CDATA[Electronics for Imaging Inc.]]></category>
		<category><![CDATA[ELGX]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELS]]></category>
		<category><![CDATA[EMC]]></category>
		<category><![CDATA[EMC Corporation]]></category>
		<category><![CDATA[Encana Corporation]]></category>
		<category><![CDATA[Endologix Inc]]></category>
		<category><![CDATA[Entegris Inc]]></category>
		<category><![CDATA[ENTG]]></category>
		<category><![CDATA[Equity Lifestyles Properties Inc]]></category>
		<category><![CDATA[ERIC]]></category>
		<category><![CDATA[ESI]]></category>
		<category><![CDATA[ETFC]]></category>
		<category><![CDATA[EVBS]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[EWBC]]></category>
		<category><![CDATA[EXPO]]></category>
		<category><![CDATA[Exponent Inc.]]></category>
		<category><![CDATA[EZCORP Inc.]]></category>
		<category><![CDATA[EZPW]]></category>
		<category><![CDATA[F5 Networks Inc.]]></category>
		<category><![CDATA[FCFS]]></category>
		<category><![CDATA[FCX]]></category>
		<category><![CDATA[FFIV]]></category>
		<category><![CDATA[Fidelity National Information Services Inc]]></category>
		<category><![CDATA[Fifth Third Bancorp]]></category>
		<category><![CDATA[First Cash Financial Services Inc]]></category>
		<category><![CDATA[First Niagara Financial Group Inc]]></category>
		<category><![CDATA[FIS]]></category>
		<category><![CDATA[FITB]]></category>
		<category><![CDATA[FLEX]]></category>
		<category><![CDATA[Flextronics International Limited]]></category>
		<category><![CDATA[FLIR]]></category>
		<category><![CDATA[FLIR Systems Inc]]></category>
		<category><![CDATA[FMX]]></category>
		<category><![CDATA[FNFG]]></category>
		<category><![CDATA[Fomento Economico Mexicano S.a.b De C.v.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[Forward Air Corporation]]></category>
		<category><![CDATA[Freeport-McMoRan Copper & Gold Inc]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[FULT]]></category>
		<category><![CDATA[Fulton Financial Corporation]]></category>
		<category><![CDATA[FWRD]]></category>
		<category><![CDATA[Gannett Company Inc]]></category>
		<category><![CDATA[Gardner Denver Inc.]]></category>
		<category><![CDATA[GCI]]></category>
		<category><![CDATA[GDI]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[Gentex Corporation]]></category>
		<category><![CDATA[GLF]]></category>
		<category><![CDATA[Glimcher Realty Trust]]></category>
		<category><![CDATA[Global Payments Inc]]></category>
		<category><![CDATA[GNTX]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[Goodrich Corporation]]></category>
		<category><![CDATA[GPN]]></category>
		<category><![CDATA[GR]]></category>
		<category><![CDATA[GRT]]></category>
		<category><![CDATA[Grupo Aeroportuario Centro Norte S.A. de C.V.]]></category>
		<category><![CDATA[Grupo Aeroportuario Del Sureste SA de CV]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Gulfmark Offshore Inc.]]></category>
		<category><![CDATA[GWW]]></category>
		<category><![CDATA[HAFC]]></category>
		<category><![CDATA[HAL]]></category>
		<category><![CDATA[Halliburton Company]]></category>
		<category><![CDATA[Hancock Holding Company]]></category>
		<category><![CDATA[Hanesbrands Inc.]]></category>
		<category><![CDATA[Hanmi Financial Corporation]]></category>
		<category><![CDATA[Harley-Davidson Inc.]]></category>
		<category><![CDATA[HAS]]></category>
		<category><![CDATA[Hasbro Inc.]]></category>
		<category><![CDATA[HBAN]]></category>
		<category><![CDATA[HBHC]]></category>
		<category><![CDATA[HBI]]></category>
		<category><![CDATA[Healthways Inc]]></category>
		<category><![CDATA[Heartland Express Inc]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[HITT]]></category>
		<category><![CDATA[Hittite Microwave Corporation]]></category>
		<category><![CDATA[HNI]]></category>
		<category><![CDATA[HNI Corporation]]></category>
		<category><![CDATA[HOG]]></category>
		<category><![CDATA[HOMB]]></category>
		<category><![CDATA[Home Bancshares Inc (Conway AR)]]></category>
		<category><![CDATA[HON]]></category>
		<category><![CDATA[Honeywell International Inc.]]></category>
		<category><![CDATA[Host Hotels & Resorts Inc.]]></category>
		<category><![CDATA[HST]]></category>
		<category><![CDATA[HTLD]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Huntington Bancshares Inc]]></category>
		<category><![CDATA[HWAY]]></category>
		<category><![CDATA[IBKR]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[ICLR]]></category>
		<category><![CDATA[ICON plc]]></category>
		<category><![CDATA[ICU Medical Inc]]></category>
		<category><![CDATA[ICUI]]></category>
		<category><![CDATA[IDEX Corporation]]></category>
		<category><![CDATA[IDEXX Laboratories Inc.]]></category>
		<category><![CDATA[IDXX]]></category>
		<category><![CDATA[IEX]]></category>
		<category><![CDATA[IIIN]]></category>
		<category><![CDATA[INFA]]></category>
		<category><![CDATA[Infinera Corporation]]></category>
		<category><![CDATA[INFN]]></category>
		<category><![CDATA[Informatica Corporation]]></category>
		<category><![CDATA[Ingersoll-Rand Company Limited]]></category>
		<category><![CDATA[Insteel Industries Inc.]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[Interactive Brokers Group Inc]]></category>
		<category><![CDATA[International Business Machines]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[IR]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[ITT Educational Services Inc.]]></category>
		<category><![CDATA[Ixia]]></category>
		<category><![CDATA[JAKK]]></category>
		<category><![CDATA[JAKKS Pacific Inc.]]></category>
		<category><![CDATA[Janus Capital Group Inc.]]></category>
		<category><![CDATA[JCI]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[JNS]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Johnson Controls Inc.]]></category>
		<category><![CDATA[Kansas City Southern]]></category>
		<category><![CDATA[Kayne Anderson Energy Development Company]]></category>
		<category><![CDATA[KED]]></category>
		<category><![CDATA[KEY]]></category>
		<category><![CDATA[KeyCorp]]></category>
		<category><![CDATA[Kinder Morgan Energy Partners LP]]></category>
		<category><![CDATA[Kinder Morgan Management LLC]]></category>
		<category><![CDATA[KMP]]></category>
		<category><![CDATA[KMR]]></category>
		<category><![CDATA[KNL]]></category>
		<category><![CDATA[Knoll Inc.]]></category>
		<category><![CDATA[KO]]></category>
		<category><![CDATA[KOF]]></category>
		<category><![CDATA[KSU]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[Lacrosse Footwear Inc.]]></category>
		<category><![CDATA[Landstar System Inc.]]></category>
		<category><![CDATA[Lare Holdings Inc]]></category>
		<category><![CDATA[LaSalle Hotel Properties]]></category>
		<category><![CDATA[Lattice Semiconductor Corporation]]></category>
		<category><![CDATA[LCC]]></category>
		<category><![CDATA[LECO]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[LHO]]></category>
		<category><![CDATA[Life Time Fitness Inc.]]></category>
		<category><![CDATA[Lincoln Electric Holdings]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Lm Ericsson Telephone Company]]></category>
		<category><![CDATA[LNCR]]></category>
		<category><![CDATA[LSCC]]></category>
		<category><![CDATA[LSTR]]></category>
		<category><![CDATA[LTM]]></category>
		<category><![CDATA[LUFK]]></category>
		<category><![CDATA[Lufkin Industries Inc.]]></category>
		<category><![CDATA[M&T Bank Corporation]]></category>
		<category><![CDATA[MAN]]></category>
		<category><![CDATA[MANH]]></category>
		<category><![CDATA[Manhattan Associates Inc.]]></category>
		<category><![CDATA[Manpower Inc.]]></category>
		<category><![CDATA[Marten Transport Limited]]></category>
		<category><![CDATA[Matthews International Corporation]]></category>
		<category><![CDATA[MATW]]></category>
		<category><![CDATA[Mb Financial Inc]]></category>
		<category><![CDATA[MBFI]]></category>
		<category><![CDATA[MBWM]]></category>
		<category><![CDATA[MCBI]]></category>
		<category><![CDATA[MCD]]></category>
		<category><![CDATA[McDonald's Corporation]]></category>
		<category><![CDATA[McMoRan Exploration Company]]></category>
		<category><![CDATA[MCRI]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[Mellanox Technologies Limited]]></category>
		<category><![CDATA[Mercantile Bank Corporation]]></category>
		<category><![CDATA[Meridian Bioscience Inc.]]></category>
		<category><![CDATA[Merit Medical Systems Inc]]></category>
		<category><![CDATA[Metrocorp Bancshares Inc.]]></category>
		<category><![CDATA[MGIC Investment Corporation]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MKS Instruments Inc.]]></category>
		<category><![CDATA[MKSI]]></category>
		<category><![CDATA[MLNX]]></category>
		<category><![CDATA[MMR]]></category>
		<category><![CDATA[MMSI]]></category>
		<category><![CDATA[MNRO]]></category>
		<category><![CDATA[MO]]></category>
		<category><![CDATA[MOH]]></category>
		<category><![CDATA[Molina Healthcare Inc.]]></category>
		<category><![CDATA[Monarch Casino & Resort Inc.]]></category>
		<category><![CDATA[Monro Muffler Brake Inc.]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MOS]]></category>
		<category><![CDATA[Mosaic Company]]></category>
		<category><![CDATA[MOSY]]></category>
		<category><![CDATA[MoSys Inc]]></category>
		<category><![CDATA[MRTN]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[MTB]]></category>
		<category><![CDATA[MTG]]></category>
		<category><![CDATA[MYE]]></category>
		<category><![CDATA[Myers Industries Inc.]]></category>
		<category><![CDATA[NAFC]]></category>
		<category><![CDATA[Nash FInch Company]]></category>
		<category><![CDATA[NCR]]></category>
		<category><![CDATA[NCR Corporation]]></category>
		<category><![CDATA[NE]]></category>
		<category><![CDATA[NetScout Systems Inc]]></category>
		<category><![CDATA[New Oriental Education & Technology Group]]></category>
		<category><![CDATA[New York Community Bancorp Inc]]></category>
		<category><![CDATA[Newfield Exploration Company]]></category>
		<category><![CDATA[NFX]]></category>
		<category><![CDATA[Noble Corporation]]></category>
		<category><![CDATA[NOK]]></category>
		<category><![CDATA[Nokia Corporation]]></category>
		<category><![CDATA[Northern Trust Corporation]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NTCT]]></category>
		<category><![CDATA[NTRS]]></category>
		<category><![CDATA[Nucor Corporation]]></category>
		<category><![CDATA[NUE]]></category>
		<category><![CDATA[NVE Corporation]]></category>
		<category><![CDATA[NVEC]]></category>
		<category><![CDATA[NVR]]></category>
		<category><![CDATA[NVR Inc.]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[NYB]]></category>
		<category><![CDATA[NYT]]></category>
		<category><![CDATA[OceanFirst Financial Corporation]]></category>
		<category><![CDATA[OCFC]]></category>
		<category><![CDATA[OFG]]></category>
		<category><![CDATA[Old Republic International Corporation]]></category>
		<category><![CDATA[Olin Corporation]]></category>
		<category><![CDATA[OLN]]></category>
		<category><![CDATA[OMAB]]></category>
		<category><![CDATA[OMC]]></category>
		<category><![CDATA[Omnicom Group Inc.]]></category>
		<category><![CDATA[ORI]]></category>
		<category><![CDATA[Oriental Financial Group Inc.]]></category>
		<category><![CDATA[Pacific Continental Corporation]]></category>
		<category><![CDATA[Packaging Corporation of America]]></category>
		<category><![CDATA[PAG]]></category>
		<category><![CDATA[Park National Corporation]]></category>
		<category><![CDATA[PBCT]]></category>
		<category><![CDATA[PCBK]]></category>
		<category><![CDATA[PCP]]></category>
		<category><![CDATA[PDS]]></category>
		<category><![CDATA[Peabody Energy Corporation]]></category>
		<category><![CDATA[PENN]]></category>
		<category><![CDATA[Penn National Gaming Inc.]]></category>
		<category><![CDATA[Penske Automotive Group Inc.]]></category>
		<category><![CDATA[Peoples United Financial Inc]]></category>
		<category><![CDATA[PEP]]></category>
		<category><![CDATA[Pepsico Inc.]]></category>
		<category><![CDATA[PetMed Express Inc.]]></category>
		<category><![CDATA[PETS]]></category>
		<category><![CDATA[PGI]]></category>
		<category><![CDATA[Philip Morris International Inc]]></category>
		<category><![CDATA[PII]]></category>
		<category><![CDATA[Pinnacle Financial Partners Inc]]></category>
		<category><![CDATA[Piper Jaffray Companies]]></category>
		<category><![CDATA[PJC]]></category>
		<category><![CDATA[PKG]]></category>
		<category><![CDATA[Platinum Underwriters Holdings Limited]]></category>
		<category><![CDATA[PLCM]]></category>
		<category><![CDATA[Plexus Corporation]]></category>
		<category><![CDATA[PLXS]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[PMC-Sierra Inc.]]></category>
		<category><![CDATA[PMCS]]></category>
		<category><![CDATA[PNC]]></category>
		<category><![CDATA[PNC Financial Services Group Inc]]></category>
		<category><![CDATA[PNFP]]></category>
		<category><![CDATA[Polaris Industries Inc.]]></category>
		<category><![CDATA[Polycom Inc.]]></category>
		<category><![CDATA[POOL]]></category>
		<category><![CDATA[Pool Corp]]></category>
		<category><![CDATA[Popular Inc]]></category>
		<category><![CDATA[PPG]]></category>
		<category><![CDATA[PPG Industries Inc.]]></category>
		<category><![CDATA[Precision Castparts Corporation]]></category>
		<category><![CDATA[Precision Drilling Trust]]></category>
		<category><![CDATA[Premiere Global Services Inc.]]></category>
		<category><![CDATA[PRK]]></category>
		<category><![CDATA[Prosperity Bancshares Inc.]]></category>
		<category><![CDATA[PRSP]]></category>
		<category><![CDATA[PTP]]></category>
		<category><![CDATA[QCOM]]></category>
		<category><![CDATA[QUALCOMM Inc]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>
		<category><![CDATA[RAI]]></category>
		<category><![CDATA[Raymond James Financial Inc.]]></category>
		<category><![CDATA[Renaissance Learning Inc.]]></category>
		<category><![CDATA[Renasant Corporation]]></category>
		<category><![CDATA[Reynolds American Inc.]]></category>
		<category><![CDATA[RHI]]></category>
		<category><![CDATA[Riverbed Technology Inc.]]></category>
		<category><![CDATA[RJF]]></category>
		<category><![CDATA[RLI]]></category>
		<category><![CDATA[RLI Corporation]]></category>
		<category><![CDATA[RLRN]]></category>
		<category><![CDATA[RNST]]></category>
		<category><![CDATA[Robert Half International Inc.]]></category>
		<category><![CDATA[Rockwell Collins Inc.]]></category>
		<category><![CDATA[RRR]]></category>
		<category><![CDATA[RSC Holdings Inc.]]></category>
		<category><![CDATA[RT]]></category>
		<category><![CDATA[Ruby Tuesday Inc.]]></category>
		<category><![CDATA[RVBD]]></category>
		<category><![CDATA[SABA]]></category>
		<category><![CDATA[Saba Software Inc.]]></category>
		<category><![CDATA[Safeway Inc.]]></category>
		<category><![CDATA[SanDisk Corporation]]></category>
		<category><![CDATA[Sandy Spring Bancorp Inc]]></category>
		<category><![CDATA[SASR]]></category>
		<category><![CDATA[SBIB]]></category>
		<category><![CDATA[Schiff Nutrition International Inc]]></category>
		<category><![CDATA[SCHL]]></category>
		<category><![CDATA[Schlumberger Limited]]></category>
		<category><![CDATA[Scholastic Corporation]]></category>
		<category><![CDATA[SCHW]]></category>
		<category><![CDATA[SCSS]]></category>
		<category><![CDATA[Seagate Technology]]></category>
		<category><![CDATA[SEI Investments Company]]></category>
		<category><![CDATA[SEIC]]></category>
		<category><![CDATA[Select Comfort Corporation]]></category>
		<category><![CDATA[Sensient Technologies Corporation]]></category>
		<category><![CDATA[SFG]]></category>
		<category><![CDATA[SFNC]]></category>
		<category><![CDATA[Sherwin-Williams Company]]></category>
		<category><![CDATA[SHW]]></category>
		<category><![CDATA[Simmons First National Corporation]]></category>
		<category><![CDATA[Skyworks Solutions Inc.]]></category>
		<category><![CDATA[SLB]]></category>
		<category><![CDATA[SLM]]></category>
		<category><![CDATA[Slm Corporation]]></category>
		<category><![CDATA[SNA]]></category>
		<category><![CDATA[Snap-on Inc.]]></category>
		<category><![CDATA[SNDK]]></category>
		<category><![CDATA[SON]]></category>
		<category><![CDATA[Sonoco Products Company]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[StanCorp Financial Group Inc.]]></category>
		<category><![CDATA[Stanley Black & Decker]]></category>
		<category><![CDATA[Stanley Furniture Company Inc]]></category>
		<category><![CDATA[State Street Corporation]]></category>
		<category><![CDATA[Steel Dynamics Inc.]]></category>
		<category><![CDATA[Sterling Bancshares Inc]]></category>
		<category><![CDATA[STI]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[STLD]]></category>
		<category><![CDATA[STLY]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[STT]]></category>
		<category><![CDATA[STX]]></category>
		<category><![CDATA[SunTrust Banks Inc.]]></category>
		<category><![CDATA[SWK]]></category>
		<category><![CDATA[SWKS]]></category>
		<category><![CDATA[SWY]]></category>
		<category><![CDATA[SXT]]></category>
		<category><![CDATA[SY Bancorp Inc.]]></category>
		<category><![CDATA[SYBT]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[T]]></category>
		<category><![CDATA[Taubman Centers Inc.]]></category>
		<category><![CDATA[TAYC]]></category>
		<category><![CDATA[Taylor Capital Group Inc]]></category>
		<category><![CDATA[TBBK]]></category>
		<category><![CDATA[TCB]]></category>
		<category><![CDATA[TCBI]]></category>
		<category><![CDATA[TCF Financial Corporation]]></category>
		<category><![CDATA[TCO]]></category>
		<category><![CDATA[TD AMERITRADE Holding Corporation]]></category>
		<category><![CDATA[TEL]]></category>
		<category><![CDATA[Temple-Inland Inc.]]></category>
		<category><![CDATA[Terex Corporation]]></category>
		<category><![CDATA[TESS]]></category>
		<category><![CDATA[TESSCO Technologies Inc.]]></category>
		<category><![CDATA[TEX]]></category>
		<category><![CDATA[Texas Capital BancShares Inc.]]></category>
		<category><![CDATA[Textron Inc.]]></category>
		<category><![CDATA[The Bancorp Inc]]></category>
		<category><![CDATA[The Bank of New York Mellon Corporation]]></category>
		<category><![CDATA[The Blackstone Group]]></category>
		<category><![CDATA[The Cheesecake Factory Incorporated]]></category>
		<category><![CDATA[The Chubb Corporation]]></category>
		<category><![CDATA[The Coca-Cola Company]]></category>
		<category><![CDATA[The New York Times Company]]></category>
		<category><![CDATA[The Travelers Companies Inc.]]></category>
		<category><![CDATA[Thomas & Betts Corporation]]></category>
		<category><![CDATA[TIN]]></category>
		<category><![CDATA[TNB]]></category>
		<category><![CDATA[Tractor Supply Company]]></category>
		<category><![CDATA[TRIB]]></category>
		<category><![CDATA[Trinity Biotech plc]]></category>
		<category><![CDATA[TRV]]></category>
		<category><![CDATA[TSCO]]></category>
		<category><![CDATA[TXT]]></category>
		<category><![CDATA[Tyco Electronics Limited]]></category>
		<category><![CDATA[UAL]]></category>
		<category><![CDATA[UBNK]]></category>
		<category><![CDATA[Ultratech Inc.]]></category>
		<category><![CDATA[UMPQ]]></category>
		<category><![CDATA[Umpqua Holdings Corporation]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[Union Pacific Corporation]]></category>
		<category><![CDATA[United Continental Holdings]]></category>
		<category><![CDATA[United Financial Bancorp]]></category>
		<category><![CDATA[United Rentals Inc]]></category>
		<category><![CDATA[United Technologies Corporation]]></category>
		<category><![CDATA[Unitedhealth Group Inc.]]></category>
		<category><![CDATA[UNP]]></category>
		<category><![CDATA[URI]]></category>
		<category><![CDATA[US Airways Group Inc.]]></category>
		<category><![CDATA[Us Bancorp]]></category>
		<category><![CDATA[USB]]></category>
		<category><![CDATA[UTEK]]></category>
		<category><![CDATA[UTX]]></category>
		<category><![CDATA[VCBI]]></category>
		<category><![CDATA[Verizon Communications Inc.]]></category>
		<category><![CDATA[VF Corporation]]></category>
		<category><![CDATA[VFC]]></category>
		<category><![CDATA[Virginia Commerce Bancorp Inc]]></category>
		<category><![CDATA[Vitran Corp Inc]]></category>
		<category><![CDATA[VIVO]]></category>
		<category><![CDATA[VMW]]></category>
		<category><![CDATA[VMware Inc.]]></category>
		<category><![CDATA[VTNC]]></category>
		<category><![CDATA[VZ]]></category>
		<category><![CDATA[W.W. Grainger Inc]]></category>
		<category><![CDATA[WABC]]></category>
		<category><![CDATA[WAL]]></category>
		<category><![CDATA[Waste Connections Inc.]]></category>
		<category><![CDATA[Watsco Inc.]]></category>
		<category><![CDATA[WCC]]></category>
		<category><![CDATA[WCN]]></category>
		<category><![CDATA[WDC]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WERN]]></category>
		<category><![CDATA[Werner Enterprises Inc.]]></category>
		<category><![CDATA[WESCO International Inc.]]></category>
		<category><![CDATA[Westamerica BanCorporation]]></category>
		<category><![CDATA[Westell Technologies Inc]]></category>
		<category><![CDATA[Western Alliance Bancorporation]]></category>
		<category><![CDATA[Western Digital Corporation]]></category>
		<category><![CDATA[Westwood Holdings Group Inc]]></category>
		<category><![CDATA[WFC]]></category>
		<category><![CDATA[WHG]]></category>
		<category><![CDATA[Whirlpool Corporation]]></category>
		<category><![CDATA[WHR]]></category>
		<category><![CDATA[Wipro Limited]]></category>
		<category><![CDATA[WIT]]></category>
		<category><![CDATA[WNI]]></category>
		<category><![CDATA[WNS]]></category>
		<category><![CDATA[WNS (Holdings) Limited]]></category>
		<category><![CDATA[WSO]]></category>
		<category><![CDATA[WSTL]]></category>
		<category><![CDATA[WYNN]]></category>
		<category><![CDATA[Wynn Resorts Limited]]></category>
		<category><![CDATA[Xerox Corporation]]></category>
		<category><![CDATA[Xilinx Inc.]]></category>
		<category><![CDATA[XLNX]]></category>
		<category><![CDATA[XRX]]></category>
		<category><![CDATA[XXIA]]></category>
		<category><![CDATA[Yahoo! Inc.]]></category>
		<category><![CDATA[YHOO]]></category>
		<category><![CDATA[ZION]]></category>
		<category><![CDATA[Zions BanCorporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79251</guid>
		<description><![CDATA[Earnings Preview 7/15/11 Second quarter earnings season is now under way, but things really start to move into high gear next week. There will be 348 firms reporting, and 108 of those are in the S&#38;P 500. By next Friday we should have a very good handle on how the overall earnings season will go. The firms reporting this week are sort of like a who&#8217;s who of U.S. industry including: Apple (AAPL), American Express (AXP), Bank of America (BAC), Caterpillar (CAT), General Electric (GE), International Business Machines (IBM), Intel (INTC), McDonald&#8217;s (MCD), Schlumberger (SLB) and Verizon (VZ). That is an interesting cross section of U.S. business. We have a relatively light economic data calendar, so earnings should be front and center, along with the sovereign debt situations on both ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/18/aapl-2011-second-quarter-earnings-preview-detailed/79251/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RDY) Dr. Reddy&#8217;s Laboratories Earns FDA Approval for Generic</title>
		<link>http://www.stockbloghub.com/2011/07/14/rdy-dr-reddys-laboratories-earns-fda-approval-for-generic/79064</link>
		<comments>http://www.stockbloghub.com/2011/07/14/rdy-dr-reddys-laboratories-earns-fda-approval-for-generic/79064#comments</comments>
		<pubDate>Thu, 14 Jul 2011 18:48:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Dreyfus Municipal Income Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79064</guid>
		<description><![CDATA[Dr. Reddy’s Laboratories (RDY) delivered yet another positive momentum within a week, as the US Food and Drug Administration (FDA) approved fondaparinux sodium injection, the company’s bioequivalent generic version of Arixtra. The drug is currently marketed by GlaxoSmithKline plc (GSK) for preventing deep vein thrombosis (DVT) in adults who are undergoing hip fracture, hip replacement, or knee replacement surgery. Dr. Reddy’s received final approval from the FDA for the 2.5 mg/ 0.5 mL, 5.0 mg/ 0.4 mL, 7.5 mg/ 0.6 mL and 10 mg/ 0.8 mL doses of fondaparinux sodium injection. Dr. Reddy’s will be manufacturing the generic version under license using a patented process that is developed by Australia based Alchemia Limited. The current approval comes close on the heels of the US launch of the generic version of Novartis ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/14/rdy-dr-reddys-laboratories-earns-fda-approval-for-generic/79064/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Gets HIV Rights from Gilead</title>
		<link>http://www.stockbloghub.com/2011/07/14/myl-mylan-gets-hiv-rights-from-gilead/79031</link>
		<comments>http://www.stockbloghub.com/2011/07/14/myl-mylan-gets-hiv-rights-from-gilead/79031#comments</comments>
		<pubDate>Thu, 14 Jul 2011 16:42:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79031</guid>
		<description><![CDATA[Mylan, Inc. (MYL) recently announced that its Indian subsidiary Matrix Laboratories has been granted future rights to produce and sell generic versions of three investigational HIV therapies of Gilead Sciences, Inc. (GILD), if and when approved. The agreement aims to expand access to HIV therapies in developing nations. The therapies include elvitegravir, an integrase inhibitor; cobicistat, an antiretroviral (ARV) boosting agent; and the &#8220;Quad,&#8221; a once-daily combination pill of elvitegravir, cobicistat and Gilead’s another HIV combination medicine Truvada (Emtriva+Viread). The rights are an extension of the non-exclusive license granted to Matrix to produce and sell active pharmaceutical ingredients and finished products, including generic versions of Viread and Truvada in 95 developing countries including India. The license has now been expanded to include 16 additional countries, the three investigational medicines and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/14/myl-mylan-gets-hiv-rights-from-gilead/79031/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Presents Afinitor Data</title>
		<link>http://www.stockbloghub.com/2011/07/12/nvs-novartis-presents-afinitor-data/78847</link>
		<comments>http://www.stockbloghub.com/2011/07/12/nvs-novartis-presents-afinitor-data/78847#comments</comments>
		<pubDate>Tue, 12 Jul 2011 16:58:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Stephan Company]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[TSC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78847</guid>
		<description><![CDATA[Recently, Novartis (NVS) presented data from a late-stage study (EXIST-1) of its cancer drug Afinitor (everolimus). The randomized, placebo-controlled, double-blind, multicenter study evaluated the safety and effectiveness of the drug compared to placebo for treating patients with subependymal giant cell astrocytomas (SEGAs) coupled with tuberous sclerosis (TS). Results from the study were presented at the International tuberous sclerosis complex (TSC) Research Conference in the US. The study revealed that treatment with Afinitor caused a 50% or more reduction in SEGA tumor size in 35% of the patients. However, no such reduction was observed in the placebo arm. SEGA refers to a benign brain tumor associated with tuberous sclerosis. TSC, which is associated with multiple disorders such as seizures, swelling in the brain, developmental delays and skin lesions, affects approximately one ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/12/nvs-novartis-presents-afinitor-data/78847/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis AG&#8217;s Lung Drug Cleared in US</title>
		<link>http://www.stockbloghub.com/2011/07/11/nvs-novartis-ags-lung-drug-cleared-in-us/78600</link>
		<comments>http://www.stockbloghub.com/2011/07/11/nvs-novartis-ags-lung-drug-cleared-in-us/78600#comments</comments>
		<pubDate>Mon, 11 Jul 2011 15:55:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78600</guid>
		<description><![CDATA[Novartis AG (NVS) recently announced that its once-daily long-acting beta2-agonist (LABA) Arcapta Neohaler (75 mcg) was cleared by the US Food and Drug Administration (FDA) for the long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema. With the approval, Arcapta becomes the first therapy in the LABA class to be approved for the indication in the US. Arcapta is already available in 150 and 300 mcg versions, under the brand name of Onbrez Breezhaler (also known as QAB 149), in the European Union. Onbrez Breezhaler (150 mcg) was also cleared in Japan recently for relief of symptoms due to airway obstruction in COPD (chronic bronchitis and emphysema). It is now approved in more than 60 countries and available in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/11/nvs-novartis-ags-lung-drug-cleared-in-us/78600/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Entangled in Legal Dispute</title>
		<link>http://www.stockbloghub.com/2011/07/08/wpi-watson-pharmaceuticals-entangled-in-legal-dispute/78658</link>
		<comments>http://www.stockbloghub.com/2011/07/08/wpi-watson-pharmaceuticals-entangled-in-legal-dispute/78658#comments</comments>
		<pubDate>Fri, 08 Jul 2011 20:49:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78658</guid>
		<description><![CDATA[The legal tussle between Watson Pharmaceuticals Inc. (WPI) and Shire plc (SHPGY) intensified, with the latter filing a patent infringement case against Watson Pharma relating to Vyvanse. Vyvanse is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children aged 6 to 17 years and adults. The lawsuit comes in response to the  abbreviated new drug application (ANDA) filed by Watson Pharma with the US Food and Drug Administration (FDA) to market a generic version of Vyvanse. We note that the marketing exclusivity for Vyvanse expires in February 2012, under the Hatch-Waxman Act. By filing a patent infringement lawsuit, Shire has ensured a 30-month stay by the FDA. Consequently, the ANDA cannot be cleared by the regulatory body before August 23, 2014 or until a court ruling, whichever ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/08/wpi-watson-pharmaceuticals-entangled-in-legal-dispute/78658/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis AG&#8217;s Afinitor Impresses Again</title>
		<link>http://www.stockbloghub.com/2011/07/07/nvs-novartis-ags-afinitor-impresses-again/78554</link>
		<comments>http://www.stockbloghub.com/2011/07/07/nvs-novartis-ags-afinitor-impresses-again/78554#comments</comments>
		<pubDate>Thu, 07 Jul 2011 17:02:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PFS]]></category>
		<category><![CDATA[Provident Financial Services Inc]]></category>
		<category><![CDATA[Stephan Company]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[TSC]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78554</guid>
		<description><![CDATA[It seems Novartis AG’s (NVS) breast cancer drug, Afinitor (everolimus), is getting into a habit of delivering positive news. Right after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Afinitor last week for the treatment of subependymal giant cell astrocytomas (SEGA), the drug impressed again this week with positive interim results from a pivotal late-stage trial (BOLERO-2). BOLERO-2 evaluated Afinitor in combination with exemestane versus placebo plus exemestane in postmenopausal women with estrogen receptor-positive locally-advanced breast cancer, whose disease progressed, despite treatment with the nonsteroidal aromatase inhibitors letrozole or anastrozole. The trial results demonstrated that patients with advanced breast cancer who were dosed Afinitor in combination with exemestane, experienced significantly extended progression-free survival (PFS), as compared to patients who received ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/07/nvs-novartis-ags-afinitor-impresses-again/78554/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire Entangled in Legal Dispute</title>
		<link>http://www.stockbloghub.com/2011/07/07/shpgy-shire-entangled-in-legal-dispute/78527</link>
		<comments>http://www.stockbloghub.com/2011/07/07/shpgy-shire-entangled-in-legal-dispute/78527#comments</comments>
		<pubDate>Thu, 07 Jul 2011 16:59:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78527</guid>
		<description><![CDATA[The legal tussle between Shire (SHPGY), Sandoz, Inc. &#8212; the generic arm of Novartis (NVS) and Amneal Pharmaceuticals &#8212; intensified with Shire filing a patent infringement case against the two companies relating to Vyvanse. Vyvanse is indicated for treating patients suffering from attention deficit hyperactive disorder (ADHD). Amneal and Sandoz have filed abbreviated new drug applications (ANDAs) with the US Food and Drug Administration (FDA) to market generic versions of Vyvanse at all doses. ADHD refers to a neurobiological disorder that is often hereditary in nature. The disease gives way to lack of attention and often results in impulsiveness and hyperactivity. We note that the marketing exclusivity for Vyvanse expires in February 2012, under the Hatch-Waxman Act. By filing patent infringement lawsuits Shire has ensured a 30-month stay by the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/07/shpgy-shire-entangled-in-legal-dispute/78527/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMD) Roche Holdings Gets Positive Data on Lucentis</title>
		<link>http://www.stockbloghub.com/2011/06/29/amd-roche-holdings-gets-positive-data-on-lucentis/77892</link>
		<comments>http://www.stockbloghub.com/2011/06/29/amd-roche-holdings-gets-positive-data-on-lucentis/77892#comments</comments>
		<pubDate>Wed, 29 Jun 2011 21:00:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Semiconductor - Broad Line]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Advanced Micro Devices Inc.]]></category>
		<category><![CDATA[AMD]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77892</guid>
		<description><![CDATA[Roche Holdings Ltd. (RHHBY) recently reported positive data from two late-stage studies (RISE and RIDE) on its eye drug, Lucentis. The studies were conducted to evaluate the safety and efficacy of the drug in patients suffering from diabetic macular edema (DME). DME leads to swelling of the retina in patients with type I or type II diabetes. The disease can cause blurred vision, severe vision loss and at times blindness. Data from the trials demonstrated that the patients, after 24 months of treatment with Lucentis, experienced significant, rapid and sustained improvement in vision compared to those who were given placebo. Roche also confirmed that patients experienced an improvement in vision within seven days of starting treatment with Lucentis. The company added that patients on Lucentis also experienced decreased retinal swelling. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/amd-roche-holdings-gets-positive-data-on-lucentis/77892/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis AG Afinitor Backed in EU</title>
		<link>http://www.stockbloghub.com/2011/06/29/nvs-novartis-ag-afinitor-backed-in-eu/77906</link>
		<comments>http://www.stockbloghub.com/2011/06/29/nvs-novartis-ag-afinitor-backed-in-eu/77906#comments</comments>
		<pubDate>Wed, 29 Jun 2011 20:55:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Arlington Asset Investment Corporation]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Stephan Company]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[TSC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77906</guid>
		<description><![CDATA[Novartis AG (NVS) received a boost recently when the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of its drug Afinitor for the treatment of subependymal giant cell astrocytomas (SEGA), a benign brain tumor associated with tuberous sclerosis (TS), in the European Union. The European Commission is expected to give its decision within the next three months. The drug will be marketed in the EU in the trade name of Votubia and will be the first medicine in the region for the treatment of this challenging disease, if approved. It is already marketed in the US as Afinitor for the disease. It is also approved in Switzerland Brazil, Colombia, Guatemala, the Philippines and South Korea to treat SEGA associated with TS. Novartis ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/nvs-novartis-ag-afinitor-backed-in-eu/77906/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(REGN) Bayer Seeks Eylea Approval in Japan</title>
		<link>http://www.stockbloghub.com/2011/06/29/regn-bayer-seeks-eylea-approval-in-japan/77928</link>
		<comments>http://www.stockbloghub.com/2011/06/29/regn-bayer-seeks-eylea-approval-in-japan/77928#comments</comments>
		<pubDate>Wed, 29 Jun 2011 20:35:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Regeneron Pharmaceuticals Inc]]></category>
		<category><![CDATA[REGN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77928</guid>
		<description><![CDATA[Germany’s Bayer (BAYRY) recently submitted an application to the Japanese Ministry of Health, Labor and Welfare (MHLW) seeking approval to market its eye treatment VEGF (vascular endothelial growth factor) trap-eye (proposed trade name: Eylea) in the country. The clearance is being sought to market the drug for treating patients suffering from the neovascular form of age-related macular degeneration (wet AMD). Bayer’s application is based on positive results from the VIEW program (VEGF trap-Eye: Investigation of Efficacy and Safety in Wet AMD) which consisted of two studies, VIEW 1 and VIEW 2. The studies evaluated the efficacy of VEGF trap-eye versus Roche/Novartis’ (RHHBY/NVS) Lucentis (ranibizumab), an anti-angiogenic agent approved for treating wet AMD. Bayer/Regeneron’s eye treatment was found to be non-inferior to Lucentis. Bayer is co-developing the candidate with Regeneron Pharmaceuticals ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/regn-bayer-seeks-eylea-approval-in-japan/77928/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Files More Abbreviated New Drug Applications</title>
		<link>http://www.stockbloghub.com/2011/06/29/wpi-watson-pharmaceuticals-files-more-abbreviated-new-drug-applications/77565</link>
		<comments>http://www.stockbloghub.com/2011/06/29/wpi-watson-pharmaceuticals-files-more-abbreviated-new-drug-applications/77565#comments</comments>
		<pubDate>Wed, 29 Jun 2011 17:11:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Consolidated Edison Inc.]]></category>
		<category><![CDATA[ED]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77565</guid>
		<description><![CDATA[Watson Pharmaceuticals Inc. (WPI) recently announced that it has filed Abbreviated New Drug Applications (ANDA) with the US Food and Drug Administration (FDA) to market its generic version of GlaxoSmithKline plc’s (GSK) Avodart, indicated for the treatment of benign prostatic hyperplasia (BPH), and Novartis AG’s (NVS) Pataday 0.2%, indicated for the treatment of ocular itching that is associated with allergic conjunctivitis. In response, Glaxo filed a lawsuit against Watson Pharma in the United States District Court for the District of Delaware, and Alcon filed a lawsuit against Watson Pharma in the United States District Court for the Southern District of Indiana. Since both companies filed a suit within 30 days of the ANDA filing, the FDA cannot approve Watson Pharma’s generic Avodart and generic Pataday until November 17, 2013 and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/wpi-watson-pharmaceuticals-files-more-abbreviated-new-drug-applications/77565/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RDY) Dr. Reddy’s Laboratories Launches Generic Levaquin</title>
		<link>http://www.stockbloghub.com/2011/06/26/rdy-dr-reddy%e2%80%99s-laboratories-launches-generic-levaquin/77444</link>
		<comments>http://www.stockbloghub.com/2011/06/26/rdy-dr-reddy%e2%80%99s-laboratories-launches-generic-levaquin/77444#comments</comments>
		<pubDate>Sun, 26 Jun 2011 17:46:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Dreyfus Municipal Income Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77444</guid>
		<description><![CDATA[Dr. Reddy’s Laboratories (RDY) recently announced the launch of its generic version of Johnson &#38; Johnson’s (JNJ) antibiotic drug, Levaquin, in the US. Data from IMS Health reveal that the branded product recorded sales of $1.1 billion in the trailing twelve months ending March 2011. Only recently Dr. Reddy’s announced the launch of three other generic products in the US. The company launched the generic versions of Pfizer Inc.’s (PFE) anti-depressant, Effexor XR, Eisai Co. Ltd.’s Alzheimer’s treatment, Aricept, and Novartis AG’s (NVS) breast cancer treatment, Femara. We believe that the launches of all these generic drugs will bring in additional revenues for Dr. Reddy’s Global Generics segment, which recorded sales of $1.2 billion in fiscal 2011 (ending March 2011), reflecting a sharp year-over-year increase of 10%. Interestingly we note ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/26/rdy-dr-reddy%e2%80%99s-laboratories-launches-generic-levaquin/77444/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Analyst Mintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/24/ctic-cell-therapeutics-analyst-mintains-neutral-on-shares/77315</link>
		<comments>http://www.stockbloghub.com/2011/06/24/ctic-cell-therapeutics-analyst-mintains-neutral-on-shares/77315#comments</comments>
		<pubDate>Fri, 24 Jun 2011 16:03:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[MDS]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Midas Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77315</guid>
		<description><![CDATA[We are maintaining a Neutral recommendation on Cell Therapeutics Inc. (CTIC) with a target price of $2.25. Cell Therapeutics Inc. based in Seattle, Washington, is focused on developing drugs for cancer. The company’s lead pipeline candidate, pixantrone, is being developed for the treatment of hematologic malignancies and solid tumors. In December 2010, Cell Therapeutics filed an appeal against the decision of the FDA in April 2010 to deny approval to pixantrone for the treatment of relapsed, aggressive non-Hodgkin&#8217;s lymphoma, or NHL, in patients who have not responded to other treatment options. The approval was denied due to concerns that the late stage trial PIX301 (which formed the basis of the NDA filing) had not sufficiently proved the effectiveness of the drug. The FDA asked Cell Therapeutics to conduct an additional ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/ctic-cell-therapeutics-analyst-mintains-neutral-on-shares/77315/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/23/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-on-shares/77291</link>
		<comments>http://www.stockbloghub.com/2011/06/23/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-on-shares/77291#comments</comments>
		<pubDate>Thu, 23 Jun 2011 19:34:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77291</guid>
		<description><![CDATA[We have maintained a Neutral rating on Alnylam Pharmaceuticals Inc. (ALNY) with a target price of $9.50 per share. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this technology to build a pipeline of drug candidates for the treatment of a wide array of diseases. Alnylam Pharmaceuticals Inc.’s first quarter loss of 38 cents per share was wider than the Zacks Consensus Estimate of 32 cents per share and also the year-ago loss of 29 cents. Lower revenues and higher research and development expenses led to the greater loss. Revenues for the reported quarter fell 15% from the prior year to $20.9 million but were in line with the Zacks Consensus ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/23/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-on-shares/77291/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Gets Setback From FDA Panel</title>
		<link>http://www.stockbloghub.com/2011/06/22/nvs-novartis-gets-setback-from-fda-panel/77188</link>
		<comments>http://www.stockbloghub.com/2011/06/22/nvs-novartis-gets-setback-from-fda-panel/77188#comments</comments>
		<pubDate>Thu, 23 Jun 2011 01:03:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CAPS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Orthologic Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77188</guid>
		<description><![CDATA[Novartis (NVS) received a setback recently when an advisory panel to the US Food and Drug Administration (FDA) recommended against approving its pipeline candidate ACZ885 for the proposed indication. Novartis was seeking approval to expand the use of ACZ885 for the treatment of patients suffering from severe gouty arthritis, commonly known as gout, who failed to derive adequate relief from the currently available options like non-steroidal anti-inflammatory drugs (NSAIDs) or colchicine. ACZ885 is currently marketed for the treatment of cryopyrin-associated periodic syndromes (CAPS) under the trade name Ilaris. In Japan, however, the drug is under review for this indication. The panel strongly backed the efficacy but was concerned about safety of ACZ885. The panel believes the candidate can be used in a narrower patient population. The panel’s recommendation was based ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/nvs-novartis-gets-setback-from-fda-panel/77188/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec and Partner Elan Announce EU Label Update for Tysabri</title>
		<link>http://www.stockbloghub.com/2011/06/22/biib-biogen-idec-and-partner-elan-announce-eu-label-update-for-tysabri/77127</link>
		<comments>http://www.stockbloghub.com/2011/06/22/biib-biogen-idec-and-partner-elan-announce-eu-label-update-for-tysabri/77127#comments</comments>
		<pubDate>Wed, 22 Jun 2011 19:16:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PIMCO Municipal Income Fund II]]></category>
		<category><![CDATA[PML]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77127</guid>
		<description><![CDATA[Recently, Biogen Idec, Inc. (BIIB) and partner Elan Corporation (ELN) announced that the European Commission (EC) has approved an update to the label for their multiple sclerosis (MS) drug Tysabri (natalizumab) in the European Union (EU). The updated label includes anti-JC Virus antibody status as an additional factor that could help stratify the risk of progressive multifocal leukoencephalopathy (PML) occurring in patients treated with Tysabri. The EC’s decision for the label update does not surprise us as in April 2011 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) had backed the inclusion of the additional risk in the Tysabri label. The updated label in the EU will provide patients (treated with Tysabri) as well as doctors additional assistance in identifying the risk of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/biib-biogen-idec-and-partner-elan-announce-eu-label-update-for-tysabri/77127/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Trial Date for Teva Pharmaceuticals / Mylan Dispute</title>
		<link>http://www.stockbloghub.com/2011/06/22/myl-trial-date-for-teva-pharmaceuticals-mylan-dispute/77026</link>
		<comments>http://www.stockbloghub.com/2011/06/22/myl-trial-date-for-teva-pharmaceuticals-mylan-dispute/77026#comments</comments>
		<pubDate>Wed, 22 Jun 2011 14:58:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Canadian Pacific Railway Limited]]></category>
		<category><![CDATA[CP]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77026</guid>
		<description><![CDATA[Mylan Inc. (MYL) received some good news recently when a US District court denied Teva Pharmaceuticals Industries’ (TEVA) motion for a summary judgment, finding no inequitable conduct in the Copaxone infringement lawsuit. The court has ordered that the trial for inequitable conduct defense will commence on July 11, 2011. The remaining issues will be tried from September 7, 2011. Teva is challenging Mylan’s application for making a generic version of Teva&#8217;s Copaxone, a top selling drug for the treatment of multiple sclerosis. Copaxone loses patent protection in 2014. In December 2010 Teva filed a Citizen Petition (CP) with the FDA asking the agency to refuse approval to generic versions of Copaxone. The company said that any generic version of Copaxone should be subject to pre-clinical studies as well as full-scale ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/myl-trial-date-for-teva-pharmaceuticals-mylan-dispute/77026/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(REGN) Regeneron Pharmaceuticals Wins Unanious FDA Panel Approval</title>
		<link>http://www.stockbloghub.com/2011/06/21/regn-regeneron-pharmaceuticals-wins-unanious-fda-panel-approval/76846</link>
		<comments>http://www.stockbloghub.com/2011/06/21/regn-regeneron-pharmaceuticals-wins-unanious-fda-panel-approval/76846#comments</comments>
		<pubDate>Tue, 21 Jun 2011 19:00:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Regeneron Pharmaceuticals Inc]]></category>
		<category><![CDATA[REGN]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76846</guid>
		<description><![CDATA[Recently, the Dermatologic and Ophthalmic Advisory Committee of the US Food and Drug Administration (FDA) issued a positive opinion and unanimously recommended the US approval of Regeneron Pharmaceuticals Inc.’s (REGN) eye treatment VEGF (vascular endothelial growth factor) trap-eye (proposed trade name: Eylea). The panel recommended the clearance of the candidate in the US for treating patients suffering from the neovascular form of age-related macular degeneration (wet AMD). A decision from the FDA is expected by August 20, 2011 (target date). Although the FDA is not bound to accept the recommendation of the advisory committee, it usually does so. We remind investors that Regeneron submitted a biologics license application (BLA) to the FDA seeking marketing approval of the drug for the wet AMD indication in February 2011. The BLA was based ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/21/regn-regeneron-pharmaceuticals-wins-unanious-fda-panel-approval/76846/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RDY) Dr. Reddy’s Laboratories Announces FDA Warning Letter</title>
		<link>http://www.stockbloghub.com/2011/06/16/rdy-dr-reddy%e2%80%99s-laboratories-announces-fda-warning-letter/76483</link>
		<comments>http://www.stockbloghub.com/2011/06/16/rdy-dr-reddy%e2%80%99s-laboratories-announces-fda-warning-letter/76483#comments</comments>
		<pubDate>Thu, 16 Jun 2011 14:27:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Dreyfus Municipal Income Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76483</guid>
		<description><![CDATA[Dr. Reddy’s Laboratories (RDY) recently announced that the US Food and Drug Administration (FDA) issued a four item warning letter regarding the company’s chemical manufacturing facility at Cuernavaca, Mexico, which produces Intermediates and Active Pharmaceutical Ingredients. In the four-item warning letter, the FDA has asked for additional data and corrective actions for certain listed items. In order to respond to the warning letter within the stipulated timeframe, Dr. Reddy’s plans to work closely with the regulatory body and resolve the matters contained in the letter. Earlier, in November last year, after inspecting Dr. Reddy’s Mexico facility, the FDA had issued Form FDA 483, with observations. The company responded to the observations by implementing a number of corrective actions. Earlier this week, Dr. Reddy’s announced the launch of three generic products ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/16/rdy-dr-reddy%e2%80%99s-laboratories-announces-fda-warning-letter/76483/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(INCY) Incyte Corporation Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/16/incy-incyte-corporation-analyst-maintains-neutral-on-shares/76486</link>
		<comments>http://www.stockbloghub.com/2011/06/16/incy-incyte-corporation-analyst-maintains-neutral-on-shares/76486#comments</comments>
		<pubDate>Thu, 16 Jun 2011 14:25:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MF]]></category>
		<category><![CDATA[MF Global Ltd]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76486</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Incyte Corporation (INCY) with a target price of $18.00. Incyte is a Wilmington, Delaware-based drug discovery and development company with a focus on oral compounds to treat HIV, inflammation and cancer. The company&#8217;s lead compound is INCB18424, an oral janus-associated kinase (JAK) antagonist. Incyte is currently seeking US approval of INCB18424 for treating patients suffering from myelofibrosis (MF), a rare bone marrow disorder. Incyte submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for INCB424 earlier in the month. The company expects to launch INCB18424 for MF in the US later this year (assuming that the FDA reviews the application on a priority basis). We believe that if INCB 18424 is approved and subsequently marketed successfully for MF ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/16/incy-incyte-corporation-analyst-maintains-neutral-on-shares/76486/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AKRX) Company News for June 07, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/06/07/akrx-company-news-for-june-07-2011-corporate-summary/75683</link>
		<comments>http://www.stockbloghub.com/2011/06/07/akrx-company-news-for-june-07-2011-corporate-summary/75683#comments</comments>
		<pubDate>Tue, 07 Jun 2011 16:57:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Akorn Inc]]></category>
		<category><![CDATA[AKRX]]></category>
		<category><![CDATA[AMED]]></category>
		<category><![CDATA[Amedisys Inc.]]></category>
		<category><![CDATA[BAP]]></category>
		<category><![CDATA[Coventry Health Care Inc.]]></category>
		<category><![CDATA[Credicorp Limited]]></category>
		<category><![CDATA[Credit Suisse Group]]></category>
		<category><![CDATA[CS]]></category>
		<category><![CDATA[CVH]]></category>
		<category><![CDATA[EXEL]]></category>
		<category><![CDATA[Exelixis Inc]]></category>
		<category><![CDATA[Gen-Probe Inc.]]></category>
		<category><![CDATA[GPRO]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Lloyds Banking Group plc]]></category>
		<category><![CDATA[LOW]]></category>
		<category><![CDATA[Lowe's Companies Inc.]]></category>
		<category><![CDATA[LYG]]></category>
		<category><![CDATA[Merge Healthcare Incorporated.]]></category>
		<category><![CDATA[MRGE]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75683</guid>
		<description><![CDATA[•    Share prices of home nursing provider Amedisys, Inc.(NASDAQ:AMED) fell 7.41% after CRT Capital reduced its earnings estimates for fiscal 2011 •    According to Canaccord Genuity, data from a trial of Exelixis, Inc&#8217;s (NASDAQ:EXEL) cancer-drug candidate could possibly worsen its regulatory strategy •    According to the Wall Street Journal, Novartis AG (NYSE:NVS) could possibly opt out from the buying race for medical test manufacturer Gen-Probe Inc (NASDAQ:GPRO) •    Merge Healthcare Inc (NASDAQ:MRGE) announced plans to buy Ophthalmic Imaging Systems (OTC:OISI) for a deal worth $30.3 million in stock •    U.S.-listed shares of Peruvian metal producer Southern Copper Corp. (NYSE:SCCO) declined 11.35%, after a former army rebel won Peru&#8217;s presidential elections •    Raymond James Financial Inc. downgraded Credicorp Ltd (NYSE:BAP) , the Peruvian financial-services firm from &#8220;Outperform&#8221; to &#8220;Underperform&#8221; rating •    ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/07/akrx-company-news-for-june-07-2011-corporate-summary/75683/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Launches New Generic Pharmaceuticals</title>
		<link>http://www.stockbloghub.com/2011/05/27/myl-mylan-launches-new-generic-pharmaceuticals/75053</link>
		<comments>http://www.stockbloghub.com/2011/05/27/myl-mylan-launches-new-generic-pharmaceuticals/75053#comments</comments>
		<pubDate>Fri, 27 May 2011 13:40:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ISTA]]></category>
		<category><![CDATA[ISTA Pharmaceuticals Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75053</guid>
		<description><![CDATA[Mylan Inc.’s (MYL) generic portfolio continued to be boosted with the launch of the generic version of Xanodyne Pharmaceutical’s pain reliever Roxicodone. The generic has been launched under a development and supply agreement with Coastal Pharmaceuticals. The product recorded sales of $325 million in US for the twelve months endied March 31, 2011 according to data released by IMS Health. We note that the launch of the generic version of the pain reliever is the latest in the series of generic launches at Mylan. A couple of days ago the company, which is one of the largest generic and specialty pharmaceutical companies across the globe, launched its generic version of Abbott Laboratories’ (ABT) Depakote Sprinkle Capsules for treating seizures. The product recorded sales of $89 million in US for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/27/myl-mylan-launches-new-generic-pharmaceuticals/75053/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Launches Generic Drugs</title>
		<link>http://www.stockbloghub.com/2011/05/21/myl-mylan-launches-generic-drugs/74321</link>
		<comments>http://www.stockbloghub.com/2011/05/21/myl-mylan-launches-generic-drugs/74321#comments</comments>
		<pubDate>Sat, 21 May 2011 13:54:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[ISTA]]></category>
		<category><![CDATA[ISTA Pharmaceuticals Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74321</guid>
		<description><![CDATA[MylanInc. (MYL) recently launched its generic version of Ista Pharmaceuticals Inc’s (ISTA) Xibrom ophthalmic solution, used for the treatment of inflammation in patients who have undergone a cataract extraction operation. The generic has been launched under a development and supply agreement with Coastal Pharmaceuticals. The branded product recorded sales of $116 million in US for the twelve months ending on March 31, 2011. Mylan also recently announced launches of generic versions of Cephalon’s (CEPH) Amrix which is a muscle relaxant and Johnson &#38; Johnson’s (JNJ) Risperdal which is used for the treatment of schizophrenia. As of May 16, 2011, the company had 169 abbreviated new drug applications (ANDAs) pending US Food and Drug Administration (FDA) approval targeting $100.7 billion in branded sales. Mylan believes that about 45 of the pending ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/21/myl-mylan-launches-generic-drugs/74321/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Meets Analyst Estimates &#8211; Sales Upbeat</title>
		<link>http://www.stockbloghub.com/2011/05/03/myl-mylan-meets-analyst-estimates-sales-upbeat/73045</link>
		<comments>http://www.stockbloghub.com/2011/05/03/myl-mylan-meets-analyst-estimates-sales-upbeat/73045#comments</comments>
		<pubDate>Tue, 03 May 2011 18:03:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73045</guid>
		<description><![CDATA[Mylan Inc.’s (MYL) first quarter 2011 earnings (excluding special items) of 44 cents per share were in line with the Zacks Consensus Estimate. A higher quarterly tax rate, increased share count and pricing pressure in Europe offset the increase in generics revenue in North America to deliver in line earnings growth. Earnings were nevertheless 22% above year-ago earnings of 36 cents per share. Quarter in Details Total revenues at Mylan climbed 12.1% over the prior year to $1.45 billion driven by increased sales of generic drugs. Revenue was also barely above the Zacks Consensus Estimate of $1.44 billion. Total revenues comprises both net revenues and other revenues from third parties. Mylan reports revenues from two segments: Generics and Specialty. Generic third party net sales, derived from sales in North America, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/03/myl-mylan-meets-analyst-estimates-sales-upbeat/73045/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Posts Solid First Quarter Sales</title>
		<link>http://www.stockbloghub.com/2011/04/27/nvs-novartis-posts-solid-first-quarter-sales/71906</link>
		<comments>http://www.stockbloghub.com/2011/04/27/nvs-novartis-posts-solid-first-quarter-sales/71906#comments</comments>
		<pubDate>Wed, 27 Apr 2011 17:54:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MF]]></category>
		<category><![CDATA[MF Global Ltd]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71906</guid>
		<description><![CDATA[Novartis (NVS) reported earnings per share of $1.41 for the first quarter of 2011, below the year-earlier earnings of $1.45 per share but well ahead of the Zacks Consensus Estimate of $1.31. The drop from the base period resulted from financing costs for the Alcon acquisition completed in April this year. An increase in the number of shares outstanding, in the quarter, following dilution from the merger also affected earnings. Also marring earnings were robust profits booked in 2009 from windfall sales of H1N1 flu vaccines that were not to be repeated in the current quarter. First quarter revenues were up a solid 16% over the prior year to $14.0 billion. Total revenues also edged past the Zacks Consensus Estimate of $13.4 billion, driven by strong performance of newly launched ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/27/nvs-novartis-posts-solid-first-quarter-sales/71906/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Five Large Cap Pharmaceuticals to Consider</title>
		<link>http://www.stockbloghub.com/2011/04/27/mrk-five-large-cap-pharmaceuticals-to-consider/72522</link>
		<comments>http://www.stockbloghub.com/2011/04/27/mrk-five-large-cap-pharmaceuticals-to-consider/72522#comments</comments>
		<pubDate>Wed, 27 Apr 2011 17:41:27 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72522</guid>
		<description><![CDATA[The Large Cap Pharma sector is the fastest rising sector on Barchart when screening for the 1 month price change.  The general investing public is very interested in this sector as evidenced by the 25,409 opinions expressed on Motley Fool on the 5 stocks I selected.  Before buying make sure a pharma fits into your asset allocation plan and then please do you own further due diligence.  Read my opinion at the end of this article.  Let&#8217;s look at these 5. Merck (MRK) &#8211;  a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/27/mrk-five-large-cap-pharmaceuticals-to-consider/72522/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec Earnings Above Estimates on Multiple Sclerosis Drugs</title>
		<link>http://www.stockbloghub.com/2011/04/26/biib-biogen-idec-earnings-above-estimates-on-multiple-sclerosis-drugs/72234</link>
		<comments>http://www.stockbloghub.com/2011/04/26/biib-biogen-idec-earnings-above-estimates-on-multiple-sclerosis-drugs/72234#comments</comments>
		<pubDate>Tue, 26 Apr 2011 15:42:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PIMCO Municipal Income Fund II]]></category>
		<category><![CDATA[PML]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72234</guid>
		<description><![CDATA[Biogen Idec (BIIB) reported first-quarter earnings per share of $1.42, 3 cents above the Zacks Consensus Estimate of $1.39 and well above the year-earlier figure of $1.04. Excluding the impact of stock-based compensation expense, first quarter 2011 earnings came in at $1.43 per share. Performance was boosted by higher multiple sclerosis (MS) drug revenues, lower costs and lower share count. Biogen has been looking to streamline its operations and increase efficiencies through the implementation of a restructuring program. The company’s restructuring program includes initiatives like streamlining of operations, shutting down of facilities, and workforce reduction. Biogen is also focusing its development efforts on neurology and biologics. First quarter revenues increased 9% to $1.20 billion, with MS drugs, Tysabri and Avonex being the primary growth drivers. Revenues were above the Zacks ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/26/biib-biogen-idec-earnings-above-estimates-on-multiple-sclerosis-drugs/72234/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

